利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.011 秒)

    Method of preparing D-ribose
    3.
    发明授权
    Method of preparing D-ribose 失效
    D-核糖的制备方法

    公开(公告)号：US4760139A

    公开(公告)日：1988-07-26

    申请号：US909911

    申请日：1986-09-22

    申请人： Claude Feniou ,  Micheline Grignon ,  Brigitte Lacourt ,  Henri Pontagnier ,  Bernadette Rezzonico

    发明人： Claude Feniou ,  Micheline Grignon ,  Brigitte Lacourt ,  Henri Pontagnier ,  Bernadette Rezzonico

    IPC分类号： C07D307/32 ,  C07H3/02 ,  C07H15/18 ,  C07H1/00 ,  C07H15/04

    CPC分类号： C07D307/32 ,  C07H15/18 ,  C07H3/02

    摘要： The present invention relates to a novel method of preparing D-ribose.In this method, a 1,5-di-O-alkyl derivative of D-xylofuranose is prepared; the hydroxyl groups in positions 2 and 3 are each substituted by a group which is preferably mesyl (CH.sub.3 SO.sub.2) or methyldithiocarbonyl, CH.sub.3 SC(=S); the 2,3-unsaturated derivative is prepared; and D-ribose is finally obtained by cis-hydoxylation of the carbon-carbon double bond, followed by acid hydrolysis of the resulting 1,5-O-dialkyl derivative.

    摘要翻译： 本发明涉及一种制备D-核糖的新方法。 在该方法中，制备D-二甲基呋喃糖的1,5-二-O-烷基衍生物; 位置2和3中的羟基各自被优选甲磺酰基（CH 3 SO 2）或甲基二硫代羰基，CH 3 SC（= S）的基团取代。 制备2,3-不饱和衍生物; 最终通过碳 - 碳双键的顺式 - 羟基化反应获得D-核糖，然后酸化所得的1,5-二-O-二烷基衍生物。

    Method and composition for reducing serum lipid levels using p-chlorophenyl p-chlorophenoxyisobutyrate
    4.
    发明授权
    Method and composition for reducing serum lipid levels using p-chlorophenyl p-chlorophenoxyisobutyrate 失效
    使用对氯苯氧基异丁酸对氯苯酯降低血清脂质水平的方法和组合物

    公开(公告)号：US4179519A

    公开(公告)日：1979-12-18

    申请号：US884497

    申请日：1978-03-08

    申请人： Francois Fauran ,  Claude Feniou ,  Jacqueline Mosser ,  Gisele Prat

    发明人： Francois Fauran ,  Claude Feniou ,  Jacqueline Mosser ,  Gisele Prat

    IPC分类号： A61K31/215 ,  A61K31/235

    CPC分类号： A61K31/215

    摘要： A method for reducing serum lipid levels in humans and animals is provided which comprises administering a hypolipidemically effective amount of p-chlorophenyl 2-(p-chlorophenoxy)-2-methylpropionate. A hypolipidemic composition is provided which comprises p-chlorophenyl 2-(p-chlorophenoxy)-2-methylpropionate, as principal active ingredient, in combination with a pharmaceutically acceptable carrier. Total serum lipids and serum cholesterol levels are significantly reduced.

    摘要翻译： 提供降低人和动物血清脂质水平的方法，其包括施用降血脂有效量的2-（对氯苯氧基）-2-甲基丙酸对氯苯酯。 提供降血脂组合物，其包含作为主要活性成分的2-（对氯苯氧基）-2-甲基丙酸对氯苯酯与药学上可接受的载体的组合。 总血清脂质和血清胆固醇水平显着降低。

    Triterpenic saponin having pharmacological potency
    5.
    发明授权
    Triterpenic saponin having pharmacological potency 失效
    三萜皂苷具有药理作用

    公开(公告)号：US4335113A

    公开(公告)日：1982-06-15

    申请号：US148932

    申请日：1980-05-12

    申请人： Henri Combier ,  Gisele Prat ,  Henri Pontagnier

    发明人： Henri Combier ,  Gisele Prat ,  Henri Pontagnier

    IPC分类号： C07H15/256 ,  A61K31/70 ,  C07H15/20

    CPC分类号： C07H15/256

    摘要： The present invention concerns a new triterpenic saponin derived from caulophyllogenin, the process for extracting it from varieties of Chrysanthellum, and its therapeutic use.This saponin is characterized as being the ester of O-.beta.-D-glucosyl-3.beta.-caulophyllogenin and an oligosaccharide comprising two units of L-rhamnose and two units of D-xylose. It is extracted from vegetable matter and purified using pressurized liquid preparative chromatographic techniques.This saponin is useful in human and veterinary therapeutics in phlebology, rheumatology, and traumatology.

    摘要翻译： 本发明涉及一种来源于胡萝卜素的新型三萜皂苷，其从菊花品种中提取的方法及其治疗用途。 该皂苷的特征在于是O-β-D-葡糖基-3β-开叶绿素的酯和包含两个单位的L-鼠李糖和两个D-木糖单位的寡糖。 从植物物质中提取并使用加压液体制备色谱技术纯化。 该皂苷可用于静脉，风湿病和创伤学中的人类和兽医治疗。

    Orthoarylideneaminophenethylamines and pharmaceutical compositions
    6.
    发明授权
    Orthoarylideneaminophenethylamines and pharmaceutical compositions 失效
    正芳芳基氨基苯乙胺和药物组合物

    公开(公告)号：US4333930A

    公开(公告)日：1982-06-08

    申请号：US237277

    申请日：1981-02-23

    申请人： Marie-Helene Creuzet ,  Claude Feniou ,  Francoise Guichard ,  Gisele Prat

    发明人： Marie-Helene Creuzet ,  Claude Feniou ,  Francoise Guichard ,  Gisele Prat

    IPC分类号： A61K31/34 ,  A61K31/341 ,  A61K31/357 ,  A61K31/36 ,  A61K31/44 ,  A61K31/4406 ,  A61K31/443 ,  A61K31/4433 ,  A61P1/00 ,  A61P25/04 ,  A61P25/20 ,  A61P25/24 ,  A61P25/26 ,  C07C67/00 ,  C07C241/00 ,  C07C251/02 ,  C07D213/53 ,  C07D213/89 ,  C07D307/52 ,  C07D317/66 ,  C07D333/22 ,  C07D405/12 ,  C07D409/12 ,  A61K31/535 ,  C07D317/58 ,  C07D413/06

    CPC分类号： C07D213/53 ,  C07D213/89 ,  C07D307/52 ,  C07D317/66 ,  C07D333/22

    摘要： Compounds, exhibiting central nervous system activity, of the formula ##STR1## wherein R.sub.1 is phenyl which is unsubstituted or substituted by at least one member selected from the group consisting of halogen, CF.sub.3, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy and COOH, orR.sub.1 is ##STR2## or R.sub.1 is a heterocycle selected from the group consisting of ##STR3## R.sub.2 R.sub.3 R.sub.4 and R.sub.5, which may be identical or different, are H or CH.sub.3 ;R.sub.6 and R.sub.7, which may be identical or different, are C.sub.1 -C.sub.6 alkyl, which may be straight-chained or branched, orR.sub.7 can be H when R.sub.6 is a branched-chain alkyl, orR.sub.6 and R.sub.7 can form, with the nitrogen to which they are bonded, a heterocycle selected from the group consisting of ##STR4## R.sub.8 R.sub.9 R.sub.10 and R.sub.11, which may be identical or different, are H, halogen, CF.sub.3, hydroxy or C.sub.1 -C.sub.4 alkoxy, or two contiguous members of R.sub.8 R.sub.9, R.sub.10 and R.sub.11 may together form a chain --O--(CH.sub.2).sub.n --O--, where n=1 or 2, or a chain --O--CH.sub.2 --O--CH.sub.2 --;and pharmaceutically acceptable addition salts thereof are disclosed, along with a method of producing the same, and pharmaceutical compositions comprising the same.

    摘要翻译： 具有下式的化合物（Ⅰ）其中R1是未被取代或被选自卤素，CF 3，C 1 -C 4烷基，C 1 -C 4烷氧基中的至少一个取代的苯基 或COOH，或R 1是或者R 1是选自下列的杂环：可以相同或不同的是H或 CH3; R6和R7可以相同或不同，可以是直链或支链的C1-C6烷基，或当R6是支链烷基或R6和R7可以与氮形成时，R7可以是H 与它们相连的杂环可以是H，卤素，CF 3，羟基或羟基，或者可以相同或不同的选自由下列组成的组的杂环：R 8 + L，R 9 + L，R 10和R 11 C 1 -C 4烷氧基或R 8 + L，R 9，R 10和R 11的两个连续成员可以一起形成-O-（CH 2）n O-链，其中n = 1或2，或链-O-CH 2 -O- CH2-; 公开了其药学上可接受的加成盐及其制备方法，以及包含其的药物组合物。